الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 211 |  |  |
| | | from | 211 | | |
Abstract
A combination of weekly pegylated interferon alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is associated with low rates of treatment success and high rates of treatment discontinuation due to side effects.
For these reasons clinician need therapeutic agents that results in higher rates of SVR and more tolerable to patients. These new therapies act on targets in the life cycle of HCV to directly inhibit viral production. These drugs are referred to as Direct Acting Antiviral (DAA) agents. Among them, NS3/4A protease inhibitors, including telaprevir and boceprevir, have recently been approved.
One of the most important new drug is PSI7977. It is safe and well tolerated in clinical. It has potent antiviral activity (pan genotype) with high barrier to resistance.
The use of multiple DAAs is currently being studied with the goal of developing INF-α sparing and INF-α free regimens.